What is the difference between salbutamol (albuterol) and levosalbutamol (levalbuterol)?

Difference Between Salbutamol and Levosalbutamol

Levosalbutamol (levalbuterol) is the pure R-enantiomer of racemic salbutamol (albuterol), containing only the therapeutically active isomer, while salbutamol is a 50:50 racemic mixture of R- and S-enantiomers—however, despite theoretical advantages, levosalbutamol has NOT demonstrated clinically superior efficacy or safety outcomes in real-world practice and should not be preferentially used over standard racemic salbutamol.

Chemical and Pharmacologic Distinction

Salbutamol exists as two mirror-image molecules (enantiomers):

• R-salbutamol (levosalbutamol): The active bronchodilator with approximately 100-fold greater binding affinity to β2-adrenergic receptors 1
• S-salbutamol: Theoretically inert or potentially harmful component

Levosalbutamol is administered at half the milligram dose of racemic albuterol to provide comparable efficacy and safety 2. For example, 0.63 mg of levosalbutamol equals approximately 1.25 mg of racemic albuterol in bronchodilator effect.

Pharmacokinetic Differences

The S-enantiomer is metabolized 8-12 times slower than the R-enantiomer by SULT1A3 (sulfotransferase), leading to:

• Higher plasma concentrations of S-salbutamol after racemic administration
• Mean exposure to R-albuterol is 13-16% less in adults and 30-32% less in children with levosalbutamol compared to equivalent doses of racemic albuterol 1

After inhalation, both enantiomers show similar concentrations initially, but S-salbutamol predominates later due to slower metabolism of the swallowed portion 3.

Clinical Evidence: The Reality Check

The most rigorous systematic review and meta-analysis found NO significant differences between levosalbutamol and racemic albuterol in acute asthma 4. Specifically:

• Respiratory rate: Mean difference 0.35 (95% CI: -0.81,1.51)
• Oxygen saturation: Mean difference -0.29 (95% CI: -0.68,0.10)
• FEV1 percent change: Mean difference -28.3 (95% CI: -59.95,3.33)
• Clinical asthma score: Mean difference -1.01 (95% CI: -5.30,3.28)
• Side effects: No significant differences

The authors explicitly concluded: "Levalbuterol should not be used over albuterol for acute asthma" 4.

Guideline Recommendations

The 2007 NAEPP Expert Panel Report 3 guidelines list both medications as equivalent options for acute asthma management 2:

• Both are acceptable short-acting β2-agonists (SABAs)
• Dosing reflects the 2:1 ratio (racemic albuterol at twice the milligram dose)
• No preferential recommendation for either agent

The guidelines note that levosalbutamol "provides comparable efficacy and safety" when dosed appropriately but do not suggest superiority 2.

Theoretical Concerns About S-Salbutamol

Some preclinical and early clinical studies suggested S-salbutamol might:

• Increase bronchial hyperresponsiveness 5
• Decrease baseline FEV1 after chronic use 5
• Increase methacholine sensitivity 5

However, well-designed clinical trials in patients with asthma have failed to find evidence of significant toxicity from S-salbutamol 3. The clinical consequences of higher S-salbutamol plasma concentrations remain unclear and appear minimal in practice.

Practical Clinical Implications

When to Use Racemic Salbutamol (Standard Choice):

• All acute asthma exacerbations (no proven advantage of levosalbutamol) 4
• Chronic asthma management
• COPD (levosalbutamol shows no consistent superiority) 6
• Cost-effective first-line therapy

Potential Consideration for Levosalbutamol:

• Patients experiencing significant tachycardia or tremor with racemic salbutamol (though evidence is mixed—some studies show less tachycardia 7, others show no difference 4)
• Individual patient response variability (rare cases where switching provides subjective benefit)

Common Pitfalls to Avoid

1. Don't assume levosalbutamol is "better" because it's pure: The theoretical advantages have not translated to meaningful clinical outcomes 4, 3

2. Don't underdose levosalbutamol: Remember the 2:1 ratio—0.63 mg levosalbutamol ≈ 1.25 mg racemic albuterol 2

3. Don't switch patients doing well on racemic albuterol: There's no evidence-based reason to change 4

4. Don't justify levosalbutamol based on S-enantiomer toxicity: This concern has not been validated in rigorous clinical trials 3

Cost Considerations

Levosalbutamol is typically more expensive than racemic salbutamol without demonstrated superior outcomes, making racemic salbutamol the more cost-effective choice for most patients 4, 8.